2014-11-18T14:38:46-06:00 2013-12-31 BDO USA LLP 8405 GREENSBORO DRIVE 7TH FLOOR MCLEAN VA 22102 990 2013-01-01 522044704 AERAS % DONNA D'AMATO AERA 3015472900 1405 RESEARCH BLVD Suite 300 ROCKVILLE MD 20850 Daniel M Reznikov CFO 3015472892 2014-11-12 true Jeffrey J Schragg P00234543 3015472892 2013 2015-11-30 17:44:51Z THOMAS EVANS 1405 RESEARCH BLVD ROCKVILLE MD 20850 75075475 false X WWW.AERAS.ORG X 1997 DC DEDICATED TO THE DEVELOPMENT OF EFFECTIVE TUBERCULOSIS (TB) VACCINES & BIOLOGICS TO PREVENT TB ACROSS ALL AGE GROUPS IN AN AFFORDABLE & SUSTAINABLE MANNER. 11 9 170 9 818725 -582211 47025200 53525841 893761 1393354 175709 116369 -36126 -41122 48058544 54994442 2132586 1934033 0 0 19671886 19003953 0 0 0 27892213 27328534 49696685 48266520 -1638141 6727922 43841249 51799335 7520117 8949247 36321132 42850088 X AERAS IS A NON-PROFIT PRODUCT DEVELOPMENT ORGANIZATION DEDICATED TO THE DEVELOPMENT OF EFFECTIVE TUBERCULOSIS (TB) VACCINES AND BIOLOGICS TO PREVENT TB ACROSS ALL AGE GROUPS IN AN AFFORDABLE AND SUSTAINABLE MANNER. AERAS UTILIZES ITS BROAD CAPABILITIES AND TECHNOLOGIES IN COLLABORATION WITH NUMEROUS PARTNERS AND STAKEHOLDERS TO SUPPORT THE DEVELOPMENT OF VACCINES AND OTHER BIOPHARMACEUTICALS TO ADDRESS TB AND OTHER SIGNIFICANT PUBLIC HEALTH NEEDS OF UNDERSERVED POPULATIONS. IN THE PURSUIT OF OUR MISSION, WE ARE GUIDED BY OUR CORE VALUES. THESE CORE VALUES EXPRESS OUR ASPIRATIONS AND THE BEHAVIORS WE WANT TO EXHIBIT AND MODEL. THEY SHAPE THE CULTURE AND CHARACTER OF AERAS AND INFORM ALL OF OUR DECISIONS AND ACTIONS. false false 6011106 Discovery/Preclinical - Aeras develops and assesses a range of vaccine platforms and variations, and explores novel approaches to enhance the effectiveness of new TB vaccines in effective prime-boost regimens. Aeras evaluates TB vaccine candidates to determine whether they have the characteristics needed to move forward to the next phase of development. Key elements include evaluation of safety, immunogenicity and the protection the candidates provide in animal models. An independent panel of vaccine experts evaluates all relevant preclinical data before a candidate is approved for entry into Phase I trials. Aeras also supports the assessment of novel assays that could be implemented at the clinical stage of development to drastically reduce the time and cost of developing new vaccines against tuberculosis. 15449094 Clinical - Aeras and its research partners have transformed the TB vaccine clinical landscape. Six vaccine candidates are undergoing testing in clinical trials in Kenya, Senegal, South Africa, the United Kingdom, and the United States with support from Aeras for protocol development, safety monitoring, regulatory and immunology. We also design and conduct epidemiology studies to estimate TB prevalence and/or incidence under real-world trial conditions to inform ongoing studies and to assess the feasibility of conducting large-scale clinical trials in TB at additional research sites in TB endemic countries, including China. 14402366 1393354 Tech Operations - Vaccine manufacturing facility located at Aeras headquarters designed to manufacture internally developed vaccine candidates based on a range of technology platforms capabilities in bacterial, viral and protein vaccines. Aeras has cGMP-compliant, end-to-end equipment and operating capabilities that meet both US FDA and European EMEA standards. Process development and manufacturing capabilities support translation from research to clinical development, including manufacturing of clinical trial materials for Aeras-sponsored trials. The Facility is also used in collaboration with external vaccine partners and contract product development services clients. 5662546 41525112 true true false false false false false false false false true false false false true true false true false true true true false false false false false false false true false false false false false false false false false false false false false true true true false false true X 70 0 170 true true true true SF HK CH false false false false false false false false X 11 9 false false false false false false false true true false false true true true true true true true true false MD X X DONNA D'AMATO 3015472923 1405 RESEARCH BLVD STE 300 ROCKVILLE MD 20850 X R GORDON DOUGLAS JR CHAIRMAN 1.0 X 0 0 0 PETER BARTON HUTT LLM DIRECTOR 1.0 X 0 0 0 HOOSEN COOVADIA MD DIRECTOR 1.0 X 0 0 0 REGINA RABINOVICH MD MPH DIRECTOR 1.0 X 0 0 0 JAMES CONNOLLY CHIEF EXECUTIVE OFFICER 1.0 X 245824 0 2859 THOMAS EVANS PRESIDENT & CEO 40.0 X X 527202 0 33655 WAYNE PISANO DIRECTOR 1.0 X 0 0 0 LOTA ZOTH DIRECTOR 1.0 X 0 0 0 GERD ZETTLMEISSEL DIRECTOR 1.0 X 0 0 0 BARRY BLOOM DIRECTOR 1.0 X 0 0 0 MARJA ESVELD DIRECTOR 1.0 X 0 0 0 ANN M GINSBERG MD PHD CHIEF MEDICAL OFFICER 40.0 X 328395 0 20738 ERIC TSAO VP, TECHNICAL OPERATIONS 40.0 X 254188 0 32332 GERARD FLEURY CHIEF FINANCIAL OFFICER 40.0 X 325836 0 32801 KEVIN SLY VP, BUSINESS DEVELOPMENT 40.0 X 275055 0 32737 RITA KHANNA DIRECTOR, LEGAL AFFAIRS 40.0 X 215588 0 17448 WENDY PENRY CHIEF HUMAN RESOURCES OFFICER 40.0 X 197512 0 28321 KARI STOEVER VP, EXTERNAL AFFAIRS 40.0 X 257539 0 24727 LEWIS SCHRAGER VP, Scientific Affairs 40.0 X 63381 0 2059 KENNETH WALKER VP, Vaccine Discovery 40.0 X 197482 0 26665 LEWELLYS BARKER DIRECTOR CLINICAL DEVELOPMENT 40.0 X 240412 0 18997 SADRITIN ISHMUKHAMEDOV DIR, GLOBAL SAFETY & PHARMACO. 40.0 X 193007 0 16833 MICHAEL BRENNAN SENIOR ADVISOR, GLOBAL AFFAIRS 40.0 X 219092 0 18073 MARGARET GOETZ DIR, BIOSTATS AND DATA MGMT 40.0 X 219024 0 13671 BARBARA SHEPHERD DIRECTOR MEDICAL WRITING 40.0 X 193184 0 20136 ROBIN GOLDSTEIN SR DIRECTOR PROJECT MANAGEMENT 40.0 X 238012 0 19586 JANICE CHAPPELL SR DIRECTOR REGULATORY AFFAIRS 40.0 X 189277 0 28371 4380010 0 390009 62 false true false Alexandria Real Estate 385 E Colorado Blvd Suite 299 PASADENA CA 91101 Landlord 4020494 The University of Cape Town WERNER BEIT SOUTH BUILDING CAPE TOWN 0 SF 7925 VACCINE DEV/RESEARCH 1550641 Triclinium Clinic Rsrch Svs PO BOX 55132 NORTHLANDS 0 SF 2116 VACCINE DEV/RESEARCH 1062519 Care First Blue Choice 840 First Street NE WASHINGTON DC 20065 Health Insurance 1018442 Quintiles Ltd PROFESSIONAL SERVICES CENTRE LIVINGSTON 0 UK EH54 6GA PROFESSIONAL SERVICE 790018 53 10179716 43346125 53525841 VACCINE MANUFACTURING 541900 1393354 574629 818725 0 1393354 192066 192066 0 0 682466 723588 -41122 0 -41122 -41122 19281748 19357445 -75697 -75697 -75697 0 0 0 0 54994442 574629 818725 75247 0 0 0 0 1934033 1934033 0 0 3611594 1984549 1627045 0 0 0 0 0 11967467 10468871 1498596 0 848408 683691 164717 0 1510088 1227166 282922 0 1066396 882369 184027 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2941412 1483230 1458182 0 0 0 0 0 769381 478792 290589 0 0 0 0 0 0 0 0 0 4392718 4135408 257310 0 942210 769913 172297 0 0 0 0 0 649082 595425 53657 0 0 0 0 0 0 0 0 0 3918814 3692393 226421 0 168953 41428 127525 0 CONTRACT SERVICES 9639550 9622724 16826 0 COLLABORATION AGREEMENTS 1147182 1147182 0 0 LAB SUPPLIES AND MATERIALS 2173999 2173894 105 0 RECRUITMENT 585233 204044 381189 0 48266520 41525112 6741408 0 300 300 3458884 17445284 1291735 11039623 47548 46035 0 0 0 0 0 0 0 0 769768 2358123 37567986 28425564 11771464 9142422 26168019 11176601 0 0 0 0 0 0 333531 590947 43841249 51799335 5411737 7127816 174145 0 225190 381476 0 0 0 0 0 0 0 0 0 0 1709045 1439955 7520117 8949247 X 10231637 7057549 26089495 35792539 0 0 36321132 42850088 43841249 51799335 X 6727922 -93533 -105433 X false true X true true true X JOHNS HOPKINS HOSPITAL BALTIMORE MD OREGON SCIENCE AND HEALTH UNIVERSITY PORTLAND OR ST LOUIS UNIVERSITY ST LOUIS MO New York University New York City NY Albert Einstein College of Medicine New York City NY University of Rochester Rochester NY Massachusetts General HospitalBrigham and Women's Boston MA University of Pittsburgh Pittsburgh PA Vaccine Research Center at NIH Bethesda MD University of Massachusetts School of Medicine Worcester MA Fred Hutchinson Cancer Research Center Seattle WA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 0 18124057 12011104 6112953 0 165615 118612 47003 0 16163730 13538147 2625583 0 3114584 2757701 356883 9142422 0 DEFERRED RENT 1373581 DEFERRED 457 PLAN 66374 1439955 X 54813847 -93533 -128184 -221717 55035564 -41122 -41122 54994442 48142553 -123967 -123967 48266520 48266520 FORM 990, SCHEDULE D, PART XI, LINE 2D CONSOLIDATED FOREIGN CURRENCY LOSS (128,206) INCOME OF AFFILIATE 1,934,055 ELIMINATIONS (1,934,033) ----------- TOTAL (128,184) FORM 990, SCHEDULE D, PART XII, LINE 2D EXPENSES OF AFFILIATE 1,768,944 ELIMINATIONS (1,934,033) RENTAL INCOME (682,466) RENTAL EXPENSE 723,588 ----------- TOTAL 123,967 FORM 990, SCHEDULE D, PART X, LINE 2 In accordance with authoritative guidance issued by the FASB, Aeras would recognize a tax liability when, despite management's belief that tax return positions are supportable, management believes that certain positions may not be fully sustained upon review by tax authorities. Liabilities for uncertain tax positions would be measured based upon the largest liability that is greater than 50% likely to be incurred on any settlement with taxing authorities. To the extent that the final tax outcome of these matters would differ from the liabilities recorded, such differences would be included in income tax expense in the period in which such determination is made. Interest and penalties, if any, related to accrued liabilities for potential tax assessments also would be included in income tax expense. Management has evaluated Aeras' tax positions and has concluded that Aeras has taken no material uncertain tax positions that require adjustment to the consolidated financial statements to comply with the provisions of this guidance. Aeras is currently under no income tax examinations in any Federal, or state or local jurisdictions. Aeras is generally no longer subject to income tax examinations by the U.S. federal, state or local tax authorities for years ended December 31, 2009 and prior. FORM 990, SCHEDULE D, PART XI, LINE 4B RENTAL INCOME 682,466 RENTAL EXPENSE (723,588) ----------- TOTAL (41,122) true Central America and the Caribbean 0 0 Program Services CLINICAL 30023 East Asia and the Pacific 1 2 Program Services PRE-CLINICAL/CLINICAL 1268797 Europe (Including Iceland and Greenland) 0 0 Program Services CLIN/TECH OPS/DISC 3252929 North America 0 0 Program Services MANU/EXT. AFFAIRS 34965 South Asia 0 0 Program Services CLIN/EXT. AFFAIRS 3084 Sub-Saharan Africa 1 17 Program Services CLINICAL 5929139 2 19 2 19 10518937 10518937 Sub-Saharan Africa SEE PART V 1934033 EFT CASH 1 true false true false false false FORM 990, SCHEDULE F, PART I, LINE 2 Aeras receives a request for support. Senior management reviews the request through the due diligence criteria approved by the Board and implemented by management. For example, the grantee must be a charity either under US law or under local law. Aeras may request governance documents from the organization, IRS determination letter (or local equivalent) indicating it is a charity, lists of executive staff and board members, and financial statements of the requestor. Upon management approval, funds are sent to the requesting organization. Copies of the request and payment are maintained at Aeras. FORM 990, SCHEDULE F, PART II, COLUMN (D) THE PURPOSE OF THE GRANT IS TO SUPPORT THE MISSION OF THE ORGANIZATION, TO DEVELOP, TEST, CHARACTERIZE, LICENSE, MANUFACTURE, AND DISTRIBUTE NEW TB VACCINES. X X true true X X X X X false false false false false false false false false ANN M GINSBERG MD PHD CHIEF MEDICAL OFFICER 320895 0 7500 0 0 0 15300 0 5438 0 349133 0 0 0 LEWELLYS BARKER DIRECTOR CLINICAL DEVELOPMENT 231687 0 8725 0 0 0 13575 0 5422 0 259409 0 0 0 ERIC TSAO VP, TECHNICAL OPERATIONS 248388 0 5800 0 0 0 15041 0 17291 0 286520 0 0 0 MICHAEL BRENNAN SENIOR ADVISOR, GLOBAL AFFAIRS 215885 0 3207 0 0 0 12821 0 5252 0 237165 0 0 0 JAMES CONNOLLY CHIEF EXECUTIVE OFFICER 100824 0 145000 0 0 0 2354 0 505 0 248683 0 0 0 THOMAS EVANS PRESIDENT & CEO 432202 0 95000 0 0 0 15300 0 18355 0 560857 0 0 0 MARGARET GOETZ DIR, BIOSTATS AND DATA MGMT 210923 0 8101 0 0 0 4184 0 9487 0 232695 0 0 0 BARBARA SHEPHERD DIRECTOR MEDICAL WRITING 186234 0 6950 0 0 0 10991 0 9145 0 213320 0 0 0 SADRITIN ISHMUKHAMEDOV DIR, GLOBAL SAFETY & PHARMACO. 187407 0 5600 0 0 0 0 0 16833 0 209840 0 0 0 GERARD FLEURY CHIEF FINANCIAL OFFICER 281571 0 44265 0 0 0 15300 0 17501 0 358637 0 0 0 KEVIN SLY VP, BUSINESS DEVELOPMENT 268055 0 7000 0 0 0 15300 0 17437 0 307792 0 0 0 RITA KHANNA DIRECTOR, LEGAL AFFAIRS 212588 0 3000 0 0 0 12441 0 5007 0 233036 0 0 0 WENDY PENRY CHIEF HUMAN RESOURCES OFFICER 187512 0 10000 0 0 0 11434 0 16887 0 225833 0 0 0 KARI STOEVER VP, EXTERNAL AFFAIRS 250039 0 7500 0 0 0 14914 0 9813 0 282266 0 0 0 KENNETH WALKER VP, Vaccine Discovery 195482 0 2000 0 0 0 11818 0 14847 0 224147 0 0 0 ROBIN GOLDSTEIN SR DIRECTOR PROJECT MANAGEMENT 235895 0 2117 0 0 0 14093 0 5493 0 257598 0 0 0 JANICE CHAPPELL SR DIRECTOR REGULATORY AFFAIRS 186477 0 2800 0 0 0 11329 0 17042 0 217648 0 0 0 FORM 990, PART VI, LINE 11B A draft version of the Form 990 is shared with the Board of Directors of Aeras and once approved it is filed with the IRS. FORM 990, PART VI, LINE 12c Aeras' policy is written to protect Aeras' interest when it is contemplating entering into a transaction or arrangement that might benefit the private interest of directors, committee members, officers, employees and retained consultants of Aeras. In connection with any actual or possible conflicts of interest, an interested person must disclose the existence of his or her interest and all material facts to the directors and members of the committee with board-delegated powers considering the proposed transaction or arrangement. After disclosure of all material facts and discussion with the person, the person shall leave the board or committee meeting while their determination of a conflict of interest is discussed and voted upon. The remaining board or committee members shall decide if a conflict of interest exists. FORM 990, PART VI, LINE 15 Aeras has a Compensation Committee which determines the CEO compensation level based on his responsibilities, size of the organization, funding levels and organization objectives. Compensation is based on comparability data, is approved by independent Board members, and the process is documented in the Board minutes. Compensation for other officers is determined by the CEO, based on the officer's responsibilities, funding levels and organization objectives. compensation is based on comparability data and is shared with independent board members. FORM 990, PART VI, LINE 19 Governing documents, including Articles of Incorporation, Bylaws, Board minutes, Conflict of Interest policy and financial statements are available upon request. FORM 990, PART III, LINE 4D Aeras also works to build relationships that support its goal to develop TB vaccines through collaboration at the global and regional levels with multi-lateral organizations such as the European Union, the European Investment Bank, and the World Health Organization, among other TB researchers and vaccine developers, as well as with donors, advocates and policymakers who can help raise awareness and support for this work. Aeras' Scientific and External Affairs departments are critical to advancing these strategic partnerships to ensure global support. FORM 990, PART XI, LINE 9 US ENTITY FOREIGN CURRENCY LOSS: $(105,433) ----------- TOTAL: $(105,433) AERAS SOUTH AFRICA BLACKRIVER PARK 1ST FLR CAPE TOWN OBSERVATORY SF 7925 CLINICAL TR SF N/A N/A NA true AERAS HONG KONG UNIT 1618 16/F MIRAMAR TOWER KOWLOON HK Holding Company HK Aeras C Corp 1 7224 1.00000 true Aeras Beijing Biological Tech Co Ltd Unit 1446 14F A Tower Pacific Beijing CH Consulting CH Aeras Hong Kong C Corp 21 301212 1.00000 true false true false false false false false false false false false false false false false false false false AERAS HONG KONG B 330000 CASH Aeras South Africa B 1934033 CASH